Adipose-Derived Stem Cell Conditioned Medium for Dry Eye Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dry eye syndrome, such as lubricants and autoserum, are inconvenient and have inconsistent effects, and there is a need for a more effective medical composition that can efficiently prevent or treat dry eye disorders by leveraging the regenerative and anti-inflammatory properties of stem cells.
Innovation Solution
A bioactive formulation comprising an adipose-derived stem cell-conditioned medium (ADSC-CM) is prepared by culturing mesenchymal stem cells in a medium supplemented with serum and mesenchymal stem cell culture adjuvant, and then harvesting a fraction less than 30 kDa, which is used topically to treat epithelial tissue disorders like dry eye syndrome.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If punctal occlusion is used to decrease tear film loss, then tear film retention is improved, but inflammatory cytokines or enzymes in the tear film increase
Solution Approach 1:
The patent extracts and removes inflammatory cytokines and enzymes from the tear film through filtration steps (0.22 μm filtration) in the preparation of conditioned medium, while retaining beneficial paracrine factors. This resolves the contradiction by eliminating harmful inflammatory components that would otherwise accumulate with tear film retention.
Solution Approach 2:
The patent uses an intermediary substance (conditioned medium containing paracrine factors) to mediate the treatment effect. This intermediary delivers anti-inflammatory and regenerative benefits without directly causing inflammation, thus resolving the contradiction between tear film retention and inflammation reduction.
2Reliability
If autologous serum drops are applied to provide lubrication and biochemical components, then some therapeutic effects are achieved, but preparation and preservation become inconvenient and effects become inconsistent
Solution Approach 1:
The patent creates a standardized copy of the therapeutic components found in autologous serum by using conditioned medium with defined composition. This standardized formulation replicates the beneficial effects while eliminating the preparation and preservation inconveniences of actual patient serum through batch production and stable storage conditions.
Solution Approach 2:
The patent changes the physical and chemical parameters of the therapeutic formulation by using conditioned medium with controlled composition, pH, and sterility. This transforms the variable, hard-to-manage autologous serum into a consistent, stable product with reproducible therapeutic effects and convenient storage requirements.
3Reliability
If stem cells are used to provide regenerative and anti-inflammatory effects, then tissue healing is improved, but tumorigenic or antigenic properties may arise
Solution Approach 1:
The patent extracts only the beneficial paracrine factors from stem cells through conditioned medium preparation, while leaving behind the stem cells themselves. This separation removes potential tumorigenic and antigenic properties while retaining the regenerative and anti-inflammatory effects of stem cell secretions.
Solution Approach 2:
The patent uses conditioned medium as an intermediary that carries the therapeutic paracrine factors without containing living stem cells. This intermediary delivers the regenerative benefits while eliminating the safety risks associated with direct stem cell transplantation.
4Ease of operation
If conventional treatment modalities are used for dry eye syndrome, then some symptomatic relief is achieved, but the treatments are not ideal in daily practice due to inconsistent effects
Solution Approach 1:
The patent changes the formulation parameters to create a standardized conditioned medium with defined composition, sterility, and stability. This standardization ensures consistent therapeutic effects across different patients and treatment instances, resolving the inconsistency problem of conventional treatments.
Solution Approach 2:
The patent creates a reproducible copy of the ideal therapeutic composition through standardized preparation protocols. This ensures that each batch of conditioned medium delivers consistent effects, unlike variable autologous serum or conventional treatments.
Data Source
AI summary
Provided is a method for preparing mesenchymal stem cell-conditioned medium, including isolating mesenchymal stem cells from a subject, maintaining the mesenchymal stem cells in a mesenchymal stem cell maintenance medium, collecting the mesenchymal stem cells at passages 2 to 5, culturing the mesenchymal stem cells in a medium supplemented with fetal bovine serum and mesenchymal stem cell culture adjuvant for hours to obtain a mesenchymal stem cell-conditioned medium, harvesting the medium and centrifuging followed by filtering. Also provided is a method for preventing or treating epithelial tissue disorder of eyes such as dry eye syndrome, including applying the medium to an eye of a subject. Further provided is a medical composition including the medium.